403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Avant Technologies Inc
(MENAFN- Baystreet) 10:11 AM EST - Avant Technologies Inc: Announced the formation of a groundbreaking Joint Venture and License Agreement aimed at revolutionizing a diabetes treatment through innovative stem cell and encapsulation technologies. The Joint Venture will now pursue a Research Collaboration Agreement to advance a proprietary differentiation process that efficiently converts stem cells into insulin-producing and regulating cells, forming the core of its therapy for type 1 and some insulin-dependent type 2 diabetes. Avant Technologies Inc
shares O are trading unchanged at $0.39.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment